Search

Displaying results 2891 - 2900 of 4690 in total
  1. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil, which was previously under development by GlaxoSmithKline (GSK), is being developed by Adherex to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), one of the world’ … Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available.

  2. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

  3. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    It is developed by AstraZeneca and is currently in phase I/II trials.

  4. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  5. Drug

    Lesopitron

    go.drugbank.com/drugs/DB04970
    Experimental

    Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.

  6. Drug

    Difelikefalin

    go.drugbank.com/drugs/DB11938
    ApprovedInvestigational

    [L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665]

  7. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...

  8. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] In June of 2024, it was additionally approved by the EMA for the same indication. … [A259028,A259033] Tofersen was granted accelerated approval from the FDA on April 25, 2023, as the first treatment for adults with ALS caused by SOD1 mutation.

  9. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients 12 years and older to be approved by

  10. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.